RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

This study tests whether adding low-dose radiation to the drug elranatamab can better kill cancer cells in people with relapsed multiple myeloma that has spread outside the bone marrow. About 34 adults whose cancer returned after prior treatments will receive radiation followed b…

This early-phase study tests two drugs, mezigdomide and talquetamab, in people with multiple myeloma that has come back or stopped responding to other treatments. The goal is to find the safest dose and see if the combination can control the cancer. About 25 adults will take part…

This phase 3 study tests a new drug, linvoseltamab, against a standard three-drug combo (EPd) in people whose multiple myeloma has returned after 1-4 prior treatments. About 410 participants will be randomly assigned to receive either linvoseltamab or EPd. The goal is to see whic…

This study is testing whether adding a drug called Epunamin to a standard chemotherapy regimen (DECP) can help people with multiple myeloma that has come back or stopped responding to treatment. The trial will enroll 48 adults aged 18 to 75 who have already tried at least one pri…

This study tests whether the drug letermovir can prevent serious CMV infections in people with relapsed/refractory multiple myeloma who are being treated with elranatamab. CMV is a common virus that can cause severe illness in patients with weakened immune systems. The study will…

This study tests a new combination of two drugs (elranatamab and isatuximab) given as shots under the skin for people with multiple myeloma that has come back or not responded to at least two prior treatments. The goal is to see if the combination can shrink or control the cancer…

This study tests a new drug, REGN17372, combined with another drug, linvoseltamab, in people whose multiple myeloma has returned or stopped responding to treatment. The goal is to find a safe dose and see if the combination shrinks tumors better than linvoseltamab alone. About 15…

This study tests whether combining two medicines, mezigdomide and elranatamab, can shrink tumors or slow disease in people with multiple myeloma that has come back or stopped responding to other treatments. About 75 adults will take part. The goal is to see how many patients achi…

This study collects information from medical records of 900 people with relapsed/refractory multiple myeloma who received teclistamab or talquetamab outside of clinical trials. The goal is to understand how well these treatments work and how they are managed in everyday practice.…